New PET scan tracks immune response in melanoma patients
NCT ID NCT05279027
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting treatment. The goal was to see if changes in the scan could predict how well the cancer responds to therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zirconium Zr 89 Crefmirlimab Berdoxam
What this could lead to
If successful, this imaging method could help doctors see early on whether immunotherapy is working in melanoma patients, potentially guiding treatment decisions.
What could go wrong
This is a very small, early-phase study with only 6 participants, so results may not apply to all patients. The imaging agent is experimental and may not reliably predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perleman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States